EVO
Evotec SE
EVO trails on the overall score without a compensating advantage in the available component scores.
UNH
UnitedHealth Group Incorporated
UNH has the edge over EVO overall, supported by stronger fundamentals and lower modeled downside.
EVO Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Under pressure |
EVO's revenue, profitability, cash flow and balance sheet are all currently under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
EVO PE Valuation
EVO has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
EVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Decline | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect EVO's losses to shrink, with revenue declining.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
UNH has the edge over EVO on the outlook, with more favorable revenue expectations.
EVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.62 | -$0.14 |
| Q1 2026 | -$0.61 | +$0.03 |
| Q4 2025 | -$0.32 | +$0.29 |
| Q3 2025 | -$0.49 | +$0.05 |
| Q2 2025 | -$0.48 | +$0.06 |
| Q1 2025 | -$0.64 | -$0.35 |
| Q4 2024 | -$0.61 | -$0.35 |
| Q3 2024 | -$0.54 | -$0.24 |
EVO lost $0.62 per share over the past year, a bigger loss than the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over EVO on earnings quality, reporting a profit while its opponent remains loss making.
EVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $162M | -15% |
| Q1 2026 | $176.9M | -20% |
| Q4 2025 | $278.7M | +13% |
| Q3 2025 | $182.1M | -11% |
| Q2 2025 | $190.2M | -6% |
| Q1 2025 | $222.2M | -4.2% |
| Q4 2024 | $245.8M | +9.9% |
| Q3 2024 | $205.4M | -5.8% |
EVO's revenue is shrinking: $162M last quarter, down 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -36% | -19 points |
| Q1 2026 | -35% | -25 points |
| Q4 2025 | 9.6% | +6.5 points |
| Q3 2025 | -27% | -13 points |
| Q2 2025 | -16% | +41 points |
| Q1 2025 | -10% | -1.3 points |
| Q4 2024 | 3.1% | +8.8 points |
| Q3 2024 | -14% | -8.1 points |
EVO's operating margin was −36% last quarter, down 19 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over EVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over EVO on profitability, with a higher operating margin.
EVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$132.8M | -4534% |
| Q1 2026 | -$7.1M | +$52.5M |
| Q4 2025 | $51.7M | -5.2% |
| Q3 2025 | -$98.8M | -724% |
| Q2 2025 | $3M | +$112.7M |
| Q1 2025 | -$59.6M | +$45.8M |
| Q4 2024 | $54.6M | +$102.8M |
| Q3 2024 | $15.8M | +$43.8M |
EVO's free cash flow was −$187M over the past year, against $14M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over EVO on cash generation, producing positive trailing cash flow while its opponent burns cash.
EVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +403K shares |
| 1 year | +0.1% | +334K shares |
| 3 years | +0.5% | +1.7M shares |
| 5 years | +8.2% | +26.9M shares |
| Available history | +19% | +56M shares |
EVO has 356M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | $171,079 |
EVO hasn't bought back shares in the past year.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over EVO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
EVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2025 | 3.4x | Elevated |
| Q2 2024 | 89.3x | High |
| Q1 2024 | 36.0x | High |
| Q4 2023 | 8.8x | High |
| Q3 2023 | 2.6x | Moderate |
| Q2 2023 | 156.6x | High |
| Q2 2022 | -2.7x | Net Cash |
| Q1 2022 | -0.9x | Net Cash |
EVO's net debt is about 3.4 years of its operating earnings (EBITDA), up from 2.6 years a year ago.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
EVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 38.1 | Neutral |
| Stochastic | 34.1 | Neutral |
EVO's weekly RSI is 38 (neutral) and its Stochastic is 34 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
EVO PE vs Healthcare Sector
| Metric | EVO | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
EVO has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
EVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.56 | 6.4% above |
| 20 week MA | $1.85 | 10% below |
| 50 week MA | $2.57 | 35% below |
| 100 week MA | $3.25 | 49% below |
| 200 week MA | $5.60 | 70% below |
EVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 70% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over EVO on trend strength, trading above more of its moving averages.
EVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.9 | $17.4 | +35% |
| 2021 | $17.4 | $22.6 | +30% |
| 2022 | $22.6 | $8.06 | -64% |
| 2023 | $8.06 | $11.7 | +46% |
| 2024 | $11.7 | $4.54 | -61% |
| 2025 | $4.54 | $3.11 | -31% |
| 2026 YTD | $3.11 | $1.66 | -47% |
EVO has finished lower in three of the last six years. It's down 47% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over EVO on returns for 2026, with the stronger performance.